Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Cash & Equivalents (2019 - 2025)

Harmony Biosciences Holdings' Cash & Equivalents history spans 7 years, with the latest figure at $647.0 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 56.39% year-over-year to $647.0 million; the TTM value through Sep 2025 reached $647.0 million, up 56.39%, while the annual FY2024 figure was $453.0 million, 45.35% up from the prior year.
  • Cash & Equivalents for Q3 2025 was $647.0 million at Harmony Biosciences Holdings, up from $489.0 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $647.0 million in Q3 2025 and bottomed at $141.2 million in Q1 2021.
  • The 5-year median for Cash & Equivalents is $311.7 million (2023), against an average of $319.6 million.
  • The largest annual shift saw Cash & Equivalents decreased 14.45% in 2021 before it soared 59.03% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $234.3 million in 2021, then grew by 22.43% to $286.9 million in 2022, then increased by 8.64% to $311.7 million in 2023, then soared by 45.35% to $453.0 million in 2024, then skyrocketed by 42.83% to $647.0 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Cash & Equivalents are $647.0 million (Q3 2025), $489.0 million (Q1 2025), and $453.0 million (Q4 2024).